{"id":512203,"date":"2021-07-13T07:03:24","date_gmt":"2021-07-13T11:03:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/"},"modified":"2021-07-13T07:03:24","modified_gmt":"2021-07-13T11:03:24","slug":"recro-enters-development-and-manufacturing-agreement-with-new-client","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/","title":{"rendered":"Recro Enters Development and Manufacturing Agreement With New Client"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">GAINESVILLE, Ga., July  13, 2021  (GLOBE NEWSWIRE) &#8212; Recro Pharma, Inc. (\u201cRecro\u201d; NASDAQ: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k1beGeOurTDVHuT10ZCfYlO-YVSMBtpBYEWt658A_eWhd49qlVXF1l_42yfQubvORILTEdYb_dcXIzDs0WRDKm3v1o21iizEystRWZG6Elo=\" rel=\"nofollow noopener\" target=\"_blank\">REPH<\/a>), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a development and cGMP manufacturing agreement with a new client. Under the terms of the agreement, Recro will provide early-stage development and manufacturing services to support the client\u2019s ongoing clinical development of an orally administered, minimally-absorbed investigational compound.<\/p>\n<p align=\"justify\">\u201cThe opportunity to support our new client\u2019s clinical development of its novel therapeutic candidate allows Recro to further highlight our unique expertise in implementing sophisticated solutions to solve complex formulation and manufacturing problems,\u201d said David Enloe, president and chief executive officer of Recro. \u201cThis agreement continues the momentum that we have generated by leveraging our decades-long experience in robust commercial GMP manufacturing for clinical-stage programs. We are excited to have been selected for this important work and look forward to a long and productive partnership.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Recro<\/strong><br \/>\n        <br \/>Recro (NASD: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ambl3RnncI7wR-U36kUHsTk6ncz7KxUVx9Ae-xVuwvg5O8kYKI5bKblJZzSMjMtD94MeXupJhcRxZAy_FIJevilvD0RazzvwU2YNPY1ZBoo=\" rel=\"nofollow noopener\" target=\"_blank\">REPH<\/a>) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.<\/p>\n<p align=\"justify\">In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients\u2019 pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.<\/p>\n<p align=\"justify\">For more information about Recro\u2019s CDMO solutions, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N_Os5HryVkdJm1cJX-s7i_9camgfMXvPIxEO_nscl8TELT7DJe4yqhELcR_MpTXHn2kMlds-BcnoDgNJUJk6gK2GPSoNWTF_jdmKfK4Hwzg=\" rel=\"nofollow noopener\" target=\"_blank\">recrocdmo.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Statement Regarding Forward Looking Statements<\/strong><br \/>\n        <br \/>This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements, among other things, relate to the Company\u2019s ability to manage costs and to achieve its financial goals; to operate under increased leverage and associated lending covenants; to pay its debt under its credit agreement and to maintain relationships with CDMO commercial partners and develop additional commercial partnerships. The words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;could&#8221;, &#8220;estimate&#8221;, \u201cupcoming\u201d, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;may&#8221;, &#8220;plan&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;will&#8221; and similar terms and phrases may be used to identify forward-looking statements in this press release. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that could cause the Company\u2019s actual outcomes to differ materially from those expressed in or underlying these forward-looking statements include the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the customer ordering patterns or inventory rebalancing or disruption in raw materials or supply chain; demand for the Company\u2019s services, which depends in part on customers\u2019 research and development and the clinical plans and market success of their products; customers&#8217; changing inventory requirements and manufacturing plans; customers and prospective customers decisions to move forward with the Company\u2019s manufacturing services; the average profitability, or mix, of the products the Company manufactures; the Company\u2019s ability to enhance existing or introduce new services in a timely manner; fluctuations in the costs, availability, and suitability of the components of the products the Company manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials, or the Company\u2019s customers facing increasing or new competition. These forward-looking statements should be considered together with the risks and uncertainties that may affect our business and future results presented herein along with those risks and uncertainties discussed in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/131fa827-c96f-4225-a9d8-949407c38c5f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contacts:\r\nStephanie Diaz (Investors)\r\nVida Strategic Partners\r\n415-675-7401\r\nsdiaz@vidasp.com\r\n\r\nTim Brons (Media)\r\nVida Strategic Partners\r\n415-675-7402\r\ntbrons@vidasp.com\r\n\r\nRyan D. Lake (CFO)\r\nRecro\r\n(484) 395-2436\r\nryan.lake@recroCDMO.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) &#8212; Recro Pharma, Inc. (\u201cRecro\u201d; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a development and cGMP manufacturing agreement with a new client. Under the terms of the agreement, Recro will provide early-stage development and manufacturing services to support the client\u2019s ongoing clinical development of an orally administered, minimally-absorbed investigational compound. \u201cThe opportunity to support our new client\u2019s clinical development of its novel therapeutic candidate allows Recro to further highlight our unique expertise in implementing sophisticated solutions to solve complex formulation and manufacturing problems,\u201d said David Enloe, president and chief executive &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Recro Enters Development and Manufacturing Agreement With New Client&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-512203","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Recro Enters Development and Manufacturing Agreement With New Client - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recro Enters Development and Manufacturing Agreement With New Client - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) &#8212; Recro Pharma, Inc. (\u201cRecro\u201d; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a development and cGMP manufacturing agreement with a new client. Under the terms of the agreement, Recro will provide early-stage development and manufacturing services to support the client\u2019s ongoing clinical development of an orally administered, minimally-absorbed investigational compound. \u201cThe opportunity to support our new client\u2019s clinical development of its novel therapeutic candidate allows Recro to further highlight our unique expertise in implementing sophisticated solutions to solve complex formulation and manufacturing problems,\u201d said David Enloe, president and chief executive &hellip; Continue reading &quot;Recro Enters Development and Manufacturing Agreement With New Client&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-13T11:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Recro Enters Development and Manufacturing Agreement With New Client\",\"datePublished\":\"2021-07-13T11:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/\"},\"wordCount\":676,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/\",\"name\":\"Recro Enters Development and Manufacturing Agreement With New Client - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=\",\"datePublished\":\"2021-07-13T11:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recro-enters-development-and-manufacturing-agreement-with-new-client\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recro Enters Development and Manufacturing Agreement With New Client\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recro Enters Development and Manufacturing Agreement With New Client - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/","og_locale":"en_US","og_type":"article","og_title":"Recro Enters Development and Manufacturing Agreement With New Client - Market Newsdesk","og_description":"GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) &#8212; Recro Pharma, Inc. (\u201cRecro\u201d; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a development and cGMP manufacturing agreement with a new client. Under the terms of the agreement, Recro will provide early-stage development and manufacturing services to support the client\u2019s ongoing clinical development of an orally administered, minimally-absorbed investigational compound. \u201cThe opportunity to support our new client\u2019s clinical development of its novel therapeutic candidate allows Recro to further highlight our unique expertise in implementing sophisticated solutions to solve complex formulation and manufacturing problems,\u201d said David Enloe, president and chief executive &hellip; Continue reading \"Recro Enters Development and Manufacturing Agreement With New Client\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-13T11:03:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Recro Enters Development and Manufacturing Agreement With New Client","datePublished":"2021-07-13T11:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/"},"wordCount":676,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/","name":"Recro Enters Development and Manufacturing Agreement With New Client - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=","datePublished":"2021-07-13T11:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODkzOSM0MjkyOTk0IzIwMTc0Mzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recro-enters-development-and-manufacturing-agreement-with-new-client\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Recro Enters Development and Manufacturing Agreement With New Client"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=512203"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512203\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=512203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=512203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=512203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}